SG10201710578TA - Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt - Google Patents
Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate saltInfo
- Publication number
- SG10201710578TA SG10201710578TA SG10201710578TA SG10201710578TA SG10201710578TA SG 10201710578T A SG10201710578T A SG 10201710578TA SG 10201710578T A SG10201710578T A SG 10201710578TA SG 10201710578T A SG10201710578T A SG 10201710578TA SG 10201710578T A SG10201710578T A SG 10201710578TA
- Authority
- SG
- Singapore
- Prior art keywords
- phthalazin
- pyrido
- triazol
- fluorophenyl
- dihydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40547610P | 2010-10-21 | 2010-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201710578TA true SG10201710578TA (en) | 2018-02-27 |
Family
ID=44903424
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013029731A SG189939A1 (en) | 2010-10-21 | 2011-10-20 | Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt |
| SG10201710578TA SG10201710578TA (en) | 2010-10-21 | 2011-10-20 | Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013029731A SG189939A1 (en) | 2010-10-21 | 2011-10-20 | Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US8735392B2 (fr) |
| EP (2) | EP2630146B1 (fr) |
| JP (6) | JP2013540158A (fr) |
| KR (4) | KR20210028747A (fr) |
| CN (1) | CN103282365B (fr) |
| AR (1) | AR083502A1 (fr) |
| AU (2) | AU2011317040B2 (fr) |
| BR (1) | BR112013009117A2 (fr) |
| CA (1) | CA2814581C (fr) |
| CY (1) | CY1123356T1 (fr) |
| DK (1) | DK2630146T3 (fr) |
| ES (1) | ES2816600T3 (fr) |
| HU (1) | HUE051535T2 (fr) |
| IL (2) | IL225789B (fr) |
| MX (1) | MX362563B (fr) |
| NZ (1) | NZ609490A (fr) |
| PL (1) | PL2630146T3 (fr) |
| PT (1) | PT2630146T (fr) |
| RU (1) | RU2598606C3 (fr) |
| SG (2) | SG189939A1 (fr) |
| SI (1) | SI2630146T1 (fr) |
| TW (2) | TWI643858B (fr) |
| WO (1) | WO2012054698A1 (fr) |
| ZA (1) | ZA201302810B (fr) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2466565T3 (es) | 2008-08-06 | 2014-06-10 | Biomarin Pharmaceutical Inc. | Inhibidores dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP) |
| ES2740424T3 (es) | 2009-03-13 | 2020-02-05 | Agios Pharmaceuticals Inc | Métodos y composiciones para trastornos relacionados con la proliferación celular |
| CN102481300B (zh) | 2009-06-29 | 2015-04-15 | 安吉奥斯医药品有限公司 | 治疗性化合物和组合物 |
| EP2491145B1 (fr) | 2009-10-21 | 2016-03-09 | Agios Pharmaceuticals, Inc. | Procédés et compositions pour des troubles relatifs à la prolifération cellulaire |
| WO2011097334A1 (fr) | 2010-02-03 | 2011-08-11 | Biomarin Pharmaceutical Inc. | Inhibiteurs à base de dihydropyridophtalazinone de la poly(adp-ribose) polymérase (parp) utilisables dans le cadre du traitement de maladies associées à un déficit en pten |
| EP2533640B1 (fr) * | 2010-02-08 | 2016-09-28 | Medivation Technologies, Inc. | Procédés de synthèse de dérivés de dihydropyridophtalazinone |
| CA2814581C (fr) | 2010-10-21 | 2019-02-12 | Biomarin Pharmaceutical Inc. | Sel tosylate de la (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h- 1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phtalazin-3(7h)-one cristallin |
| DK2704721T3 (en) | 2011-05-03 | 2018-07-09 | Agios Pharmaceuticals Inc | Pyruvate kinase activators for therapeutic use |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CA2855948C (fr) * | 2011-08-11 | 2020-07-28 | Bayer Cropscience Ag | Cetoenols a substitution 1,2,4-triazolyle |
| WO2013028495A1 (fr) * | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Inhibiteurs dihydropyridophthalazinone de poly (adp-ribose) polymérase (parp) pour le traitement du myélome multiple |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| US10202339B2 (en) | 2012-10-15 | 2019-02-12 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| WO2015003355A2 (fr) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Composés thérapeutiquement actifs et leurs méthodes d'utilisation |
| CN105593215B (zh) | 2013-07-11 | 2019-01-15 | 安吉奥斯医药品有限公司 | 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物 |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015003360A2 (fr) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Composés thérapeutiquement actifs et leurs méthodes d'utilisation |
| US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| SG11201606689VA (en) | 2014-02-13 | 2016-09-29 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
| ES2750956T3 (es) | 2014-02-13 | 2020-03-30 | Incyte Corp | Ciclopropilaminas como inhibidores de LSD1 |
| RS62178B1 (sr) * | 2014-03-14 | 2021-08-31 | Les Laboratoires Servier Sas | Farmaceutske kompozicije terapeutski aktivnih jedinjenja |
| KR102400737B1 (ko) | 2014-03-14 | 2022-05-20 | 아지오스 파마슈티컬스 아이엔씨. | 치료적으로 활성인 화합물의 약제학적 조성물 |
| US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| AU2015296289B2 (en) * | 2014-07-31 | 2020-02-27 | Medivation Technologies Llc | Coformer salts of (2S,3S)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them |
| NZ735998A (en) | 2015-04-03 | 2024-08-30 | Incyte Holdings Corp | Heterocyclic compounds as lsd1 inhibitors |
| US11234976B2 (en) | 2015-06-11 | 2022-02-01 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
| NZ740186A (en) | 2015-08-12 | 2024-07-05 | Incyte Holdings Corp | Salts of an lsd1 inhibitor |
| CN108697698B (zh) | 2015-10-15 | 2021-12-03 | 阿吉奥斯制药公司 | 用于治疗恶性肿瘤的组合疗法 |
| EP4403173A3 (fr) | 2015-10-15 | 2024-10-09 | Les Laboratoires Servier | Polythérapie pour le traitement de tumeurs malignes |
| WO2017075091A1 (fr) * | 2015-10-26 | 2017-05-04 | Medivation Technologies, Inc. | Traitement du cancer du poumon à petites cellules avec un inhibiteur de parp |
| CA2997859C (fr) | 2016-02-29 | 2024-06-04 | F. Hoffmann-La Roche Ag | Compositions de formes galeniques comprenant un inhibiteur de la tyrosine kinase de bruton |
| CN111225685A (zh) | 2017-10-13 | 2020-06-02 | 默克专利股份有限公司 | Parp抑制剂和pd-1轴结合拮抗剂的组合 |
| TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
| US11368702B2 (en) | 2018-06-04 | 2022-06-21 | Lg Electronics, Inc. | Method and device for processing video signal by using affine motion prediction |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| US10942500B2 (en) * | 2018-06-11 | 2021-03-09 | Purdue Research Foundation | System architecture and method of processing data therein |
| US10382772B1 (en) * | 2018-07-02 | 2019-08-13 | Tencent America LLC | Method and apparatus for video coding |
| JP7408621B2 (ja) | 2018-07-13 | 2024-01-05 | マジック リープ， インコーポレイテッド | ディスプレイの両眼変形補償のためのシステムおよび方法 |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| EP3876940A1 (fr) | 2018-11-05 | 2021-09-15 | Pfizer Inc. | Combinaisons pour le traitement du cancer |
| US20240209061A1 (en) | 2020-03-09 | 2024-06-27 | Pfizer Inc. | Fusion proteins and uses thereof |
| US20230414522A1 (en) | 2020-11-13 | 2023-12-28 | Pfizer Inc. | Talazoparib soft gelatin capsule dosage form |
| EP4256088A1 (fr) | 2020-12-07 | 2023-10-11 | Pfizer Inc. | Procédés d'identification d'une tumeur sensible au traitement par le talazoparib et procédés de traitement associés |
| BR112023018906A2 (pt) | 2021-03-24 | 2023-10-10 | Astellas Pharma Inc | Combinação de talazoparib e um antiandrógeno para o tratamento de câncer de próstata metastático sensível à castração com mutação no gene ddr |
| WO2023131894A1 (fr) | 2022-01-08 | 2023-07-13 | Pfizer Inc. | Perte d'hétérozygotie génomique en tant que biomarqueur prédictif pour le traitement par le talazoparib et méthodes de traitement de cette perte d'hétérozygotie génomique |
| WO2023201338A1 (fr) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Polythérapie comprenant un inhibiteur de mat2a et un inhibiteur de parp |
| WO2023233295A1 (fr) | 2022-06-01 | 2023-12-07 | Ideaya Biosciences, Inc. | Dérivés de thiadiazolyle utilisés en tant qu'inhibiteurs d'adn polymérase thêta et leurs utilisations |
| TW202425975A (zh) | 2022-10-02 | 2024-07-01 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202425976A (zh) | 2022-12-17 | 2024-07-01 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4415504A (en) | 1981-09-21 | 1983-11-15 | Tanabe Seiyaku Co., Ltd. | p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine |
| JPS58225065A (ja) | 1982-06-21 | 1983-12-27 | Nippon Shinyaku Co Ltd | ２−キノロン誘導体 |
| US5328905A (en) | 1987-07-20 | 1994-07-12 | Duphar International Research B.V. | 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives |
| GB9505538D0 (en) | 1995-03-18 | 1995-05-03 | Ciba Geigy Ag | New compounds |
| ID19155A (id) | 1996-12-13 | 1998-06-18 | Tanabe Seiyaku Co | Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya |
| DE19727410A1 (de) | 1997-06-27 | 1999-01-07 | Hoechst Schering Agrevo Gmbh | 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| TW430656B (en) | 1997-12-03 | 2001-04-21 | Dainippon Ink & Chemicals | Quinolinone derivative, method for preparing the same, and anti-allergic agent |
| JP2002515490A (ja) | 1998-05-15 | 2002-05-28 | ギルフォード ファーマシューティカルズ インコーポレイテッド | Ｐａｒｐ活性を抑制する縮合三環化合物 |
| DE19921567A1 (de) | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
| JP2001302669A (ja) | 2000-04-18 | 2001-10-31 | Meiji Seika Kaisha Ltd | 三環性フタラジノン誘導体 |
| JP2002284699A (ja) | 2001-03-28 | 2002-10-03 | Sumitomo Pharmaceut Co Ltd | 視細胞変性疾患治療剤 |
| AR036081A1 (es) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
| SE0102315D0 (sv) | 2001-06-28 | 2001-06-28 | Astrazeneca Ab | Compounds |
| CN100348587C (zh) * | 2002-02-19 | 2007-11-14 | 小野药品工业株式会社 | 稠合哒嗪衍生物化合物和含这些化合物作为活性成份的药物 |
| EP1340819A1 (fr) | 2002-02-28 | 2003-09-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Marqueurs de microsatellites |
| GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
| EP1400244A1 (fr) | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | Nouveaux quinazolinones spirocondensés et leur utilisation comme inhibiteurs de la phosphodiesterase |
| JPWO2004043959A1 (ja) | 2002-11-12 | 2006-03-09 | 持田製薬株式会社 | 新規ｐａｒｐ阻害剤 |
| CA2517629C (fr) | 2003-03-12 | 2011-07-12 | Kudos Pharmaceuticals Limited | Derives de phtalazinone |
| EP1633362B1 (fr) | 2003-05-28 | 2012-09-26 | Eisai Inc. | Composes, procedes et compositions pharmaceutiques destines a l'inhibition de la parp |
| EP1716125B1 (fr) | 2004-02-18 | 2013-06-19 | AstraZeneca AB | Composes de tetrazole et leur utilisation comme antagonistes de recepteurs de glutamate metabotropiques |
| GB0612971D0 (en) | 2006-06-30 | 2006-08-09 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| KR20100007956A (ko) | 2007-05-03 | 2010-01-22 | 화이자 리미티드 | 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체 |
| US20110027226A1 (en) | 2007-08-22 | 2011-02-03 | 4Sc Ag | Indolopyridines as inhibitors of the kinesin spindle protein (eg5) |
| EP2247600A4 (fr) | 2008-02-06 | 2011-09-14 | Biomarin Pharm Inc | Inhibiteurs à base de composés benzoxazole-carboxamide de l activité poly(adp-ribose)polymérase (parp) |
| ES2466565T3 (es) | 2008-08-06 | 2014-06-10 | Biomarin Pharmaceutical Inc. | Inhibidores dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP) |
| KR20110053424A (ko) | 2008-08-12 | 2011-05-23 | 베링거 인겔하임 인터내셔날 게엠베하 | 사이클로알킬-치환된 피페라진 화합물의 제조 방법 |
| WO2011097334A1 (fr) | 2010-02-03 | 2011-08-11 | Biomarin Pharmaceutical Inc. | Inhibiteurs à base de dihydropyridophtalazinone de la poly(adp-ribose) polymérase (parp) utilisables dans le cadre du traitement de maladies associées à un déficit en pten |
| US20110190266A1 (en) | 2010-02-04 | 2011-08-04 | Daniel Chu | 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) |
| EP2533640B1 (fr) | 2010-02-08 | 2016-09-28 | Medivation Technologies, Inc. | Procédés de synthèse de dérivés de dihydropyridophtalazinone |
| WO2011130661A1 (fr) | 2010-04-16 | 2011-10-20 | Biomarin Pharmaceutical Inc. | Méthodes d'utilisation d'inhibiteurs dihydropyridophthalazinoniques de la poly(adp-ribose) polymérase (parp) |
| WO2011140009A1 (fr) | 2010-05-04 | 2011-11-10 | Biomarin Pharmaceutical Inc. | Procédés d'utilisation de glycopeptides semi-synthétiques en tant qu'agents antibactériens |
| CA2814581C (fr) | 2010-10-21 | 2019-02-12 | Biomarin Pharmaceutical Inc. | Sel tosylate de la (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h- 1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phtalazin-3(7h)-one cristallin |
| WO2012166151A1 (fr) | 2011-06-03 | 2012-12-06 | Biomarin Pharmaceutical Inc. | Utilisation d'inhibiteurs de dihydropyridophtalazinone de poly(adp-ribose) polymérase (parp) dans le traitement d'un syndrome myélodysplasique (mds) et d'une leucémie myéloïde aiguë (aml) |
| WO2013028495A1 (fr) | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Inhibiteurs dihydropyridophthalazinone de poly (adp-ribose) polymérase (parp) pour le traitement du myélome multiple |
| US20130053365A1 (en) | 2011-08-30 | 2013-02-28 | Biomarin Pharmaceutical, Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| WO2015069851A1 (fr) | 2013-11-07 | 2015-05-14 | Biomarin Pharmaceutical Inc. | Intermédiaires de triazole utiles dans la synthèse de n-alkyltriazolecarbaldéhyde protégés |
| AU2015296289B2 (en) | 2014-07-31 | 2020-02-27 | Medivation Technologies Llc | Coformer salts of (2S,3S)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them |
-
2011
- 2011-10-20 CA CA2814581A patent/CA2814581C/fr active Active
- 2011-10-20 EP EP11777005.7A patent/EP2630146B1/fr active Active
- 2011-10-20 HU HUE11777005A patent/HUE051535T2/hu unknown
- 2011-10-20 MX MX2013004195A patent/MX362563B/es active IP Right Grant
- 2011-10-20 EP EP20175014.8A patent/EP3757106A1/fr not_active Withdrawn
- 2011-10-20 CN CN201180062085.0A patent/CN103282365B/zh active Active
- 2011-10-20 KR KR1020217006784A patent/KR20210028747A/ko not_active Application Discontinuation
- 2011-10-20 DK DK11777005.7T patent/DK2630146T3/da active
- 2011-10-20 KR KR1020197030773A patent/KR20190120458A/ko not_active Application Discontinuation
- 2011-10-20 SI SI201131903T patent/SI2630146T1/sl unknown
- 2011-10-20 AR ARP110103892A patent/AR083502A1/es not_active Application Discontinuation
- 2011-10-20 RU RU2013123036A patent/RU2598606C3/ru active Protection Beyond IP Right Term
- 2011-10-20 PL PL11777005T patent/PL2630146T3/pl unknown
- 2011-10-20 ES ES11777005T patent/ES2816600T3/es active Active
- 2011-10-20 NZ NZ609490A patent/NZ609490A/en unknown
- 2011-10-20 KR KR1020137012297A patent/KR20140009181A/ko active Application Filing
- 2011-10-20 JP JP2013535079A patent/JP2013540158A/ja active Pending
- 2011-10-20 KR KR1020187016905A patent/KR20180069132A/ko active Application Filing
- 2011-10-20 WO PCT/US2011/057039 patent/WO2012054698A1/fr active Application Filing
- 2011-10-20 TW TW105123467A patent/TWI643858B/zh active
- 2011-10-20 US US13/277,607 patent/US8735392B2/en active Active
- 2011-10-20 SG SG2013029731A patent/SG189939A1/en unknown
- 2011-10-20 TW TW100138150A patent/TWI557123B/zh active
- 2011-10-20 PT PT117770057T patent/PT2630146T/pt unknown
- 2011-10-20 BR BR112013009117A patent/BR112013009117A2/pt not_active Application Discontinuation
- 2011-10-20 SG SG10201710578TA patent/SG10201710578TA/en unknown
- 2011-10-20 AU AU2011317040A patent/AU2011317040B2/en active Active
-
2013
- 2013-04-17 IL IL225789A patent/IL225789B/en active IP Right Grant
- 2013-04-18 ZA ZA2013/02810A patent/ZA201302810B/en unknown
-
2014
- 2014-04-14 US US14/252,668 patent/US20140228369A1/en not_active Abandoned
-
2016
- 2016-11-18 JP JP2016224670A patent/JP2017061526A/ja active Pending
-
2017
- 2017-03-07 AU AU2017201564A patent/AU2017201564B2/en active Active
- 2017-07-17 US US15/651,735 patent/US10189837B2/en active Active
-
2018
- 2018-10-11 JP JP2018192521A patent/JP2019034951A/ja not_active Withdrawn
-
2019
- 2019-12-17 IL IL271497A patent/IL271497A/en unknown
-
2020
- 2020-07-09 JP JP2020118281A patent/JP2020169209A/ja not_active Withdrawn
- 2020-09-22 CY CY20201100893T patent/CY1123356T1/el unknown
-
2022
- 2022-08-02 JP JP2022123448A patent/JP2022140637A/ja not_active Withdrawn
-
2024
- 2024-08-07 JP JP2024130494A patent/JP2024150772A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271497A (en) | Tosylate salt of (S8, R9)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-H1- 4,2,1-triazol-5-yl)-9,8-dihydro-H2 -Crystalline pyrido[2,3,4-de]phthalazine-3(H3)-one | |
| ZA201209632B (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | |
| PT2477648T (pt) | Terapia sinérgica anti-cd47 para cancros hematológicos | |
| ZA201300100B (en) | Indolizine derivatives,process for the preparation thereof and therapeutic use thereof | |
| EP2549947A4 (fr) | Implant chirurgical tridimensionnel composite | |
| ZA201107350B (en) | Imidazo [2 1 b] [1, 3, 4] thiadiazole derivatives | |
| IL224450B (en) | Crystalline forms of pyrimido[6,1-a] isoquinolin-4-one compounds | |
| IL229993A (en) | 8 - Alkoxy [1,2,4] triazolo [5,1 – c] pyrimidine– 2 | |
| IL222080B (en) | 6-alkyl-thieno[2,3-c]quinolin-4(5h)-one derivatives | |
| IL246247A0 (en) | Use of an anti-human prolactin receptor in the preparation of a drug to inhibit the growth of cancer | |
| EP2624834A4 (fr) | Composés macrocycliques à base de lactone et leurs procédés d'utilisation | |
| IL220448A (en) | Pyridine [3,2 - d] Pyrimidine - 7 (8h) - Their medical uses and uses | |
| IL222351A (en) | Process for making derivatives 4,1-diethylene-di (3-pyroline) -tetrone | |
| EP2511276A4 (fr) | Dérivé de pyrrolo[2,3-d]pyrimidine | |
| EP2565194A4 (fr) | DÉRIVÉ IMIDAZO[1,2-a]PYRIDINE | |
| HK1185882A1 (en) | Pyrazino[2,3-d]isoxazole derivative [23-d] | |
| ZA201303580B (en) | Oxazolo [5,4-b]pyridin-5-yl compounds and their use for the treatment of cancer | |
| EP2623053A4 (fr) | Support de fraise chirurgicale | |
| PL2477990T3 (pl) | Pochodne 5-fenylopirazolopirydyny, ich wytwarzanie oraz ich zastosowanie terapeutyczne | |
| EP2651937B8 (fr) | Dérivé imidazo[4,5-c]quinolin-1-yle utile en thérapie | |
| AU2010902149A0 (en) | Safe drink detector | |
| AU2011246168A1 (en) | Imidazo[1,2-a]pyridine derivative |